Migraine Without Aura Clinical Trial
Official title:
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load
The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by calcitonin gene-related peptide (CGRP) compared to patients with few genetic loci associated with migraine (low genetic load).
Migraine is a very prevalent neurological disorder with a strong genetic factor. The common forms of migraine have a multifactorial and polygenic pattern of inheritance and genetics research is crucial for a deeper understanding of migraine mechanisms. Recently, 12 genetic loci have been identified to be associated with migraine with (MA) and without aura (MA) in four large genome-wide association studies (GWAS). The functional consequences of these genetic loci in humans are yet unknown. Calcitonin gene-related peptide (CGRP) is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. CGRP can induce migraine attacks in MO patients via an adenosine monophosphate (cAMP) dependent pathway and CGRP antagonism is efficient in the treatment of migraine attacks. Also, a recent study has showed that intracellular accumulation of cAMP is crucial for the induction of migraine attacks. However, CGRP does not cause migraine attacks in familial hemiplegic migraine (FHM), an autosomal dominant subtype of MA. The phenotype of the migraine inducing effects of CGRP might therefore be linked to some of the 12 genetic susceptibility loci that have been identified. One of the genetic loci (rs13208321) is located in a gene (FHL5) that is associated with the regulation of cAMP-responsive elements. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01687660 -
Acupuncture for Migraine Prophylaxis
|
N/A | |
Completed |
NCT00363532 -
Functional MRI (fMRI) in CGRP Induced Migraine
|
N/A | |
Completed |
NCT00123201 -
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
|
Phase 2 | |
Completed |
NCT04406649 -
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
|
Phase 3 | |
Completed |
NCT03874832 -
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05565001 -
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
|
N/A | |
Completed |
NCT04533568 -
Ibuprofen in Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Recruiting |
NCT05416476 -
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
|
Phase 3 | |
Completed |
NCT04636359 -
Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging.
|
N/A | |
Completed |
NCT00534560 -
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
|
Phase 2 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Completed |
NCT00380263 -
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
|
N/A | |
Completed |
NCT00334178 -
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
|
Phase 3 | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Recruiting |
NCT06414044 -
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
|
||
Completed |
NCT03472378 -
Can DFN-15 Terminate Migraine With Allodynia?
|
Phase 2 | |
Recruiting |
NCT05211154 -
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
|
Phase 4 |